<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226356</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-IRB-0048/04/04</org_study_id>
    <nct_id>NCT00226356</nct_id>
  </id_info>
  <brief_title>Natural Supplements for Unipolar Depression</brief_title>
  <official_title>Phase 4 Study: An Open Study of the Efficacy and Tolerability in Unipolar Depression of Augmentation of the One-Carbon Cycle With L-Methionine, Betaine and Folate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <brief_summary>
    <textblock>
      This study is being conducted to determine the clinical response rate for the regimen of
      L-methionine, betaine and folate for unipolar depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is 6 weeks long, with 9 clinical visits.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive symptoms</measure>
  </primary_outcome>
  <enrollment>20</enrollment>
  <condition>Unipolar Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplements of L-methionine, betaine and folate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of a MDD or DDNOS; clinical indication for treatment of current
             depressive symptoms; HDS &gt; 18; women of reproductive potential must use an acceptable
             method of birth control

        Exclusion Criteria:

          -  Treatment with another psychotropic drug; history of mania or hypomania; history of
             bipolar illness in first-degree relatives; active homicidality; pregnant; trying to
             become pregnant, or nursing; unstable medical condition; current substance abuse in
             the past month; history of sulfa allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert T Dunn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Health Alliance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Stan, AB</last_name>
    <phone>617-591-6116</phone>
    <email>vstan@challiance.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Stan, AB</last_name>
      <phone>617-591-6116</phone>
      <email>vstan@challiance.org</email>
    </contact>
    <investigator>
      <last_name>Robert T Dunn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <lastchanged_date>October 19, 2006</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
